MSLE
HEALTHCARESatellos Bioscience Inc
$7.70-0.30 (-3.75%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving MSLE Today?
No stock-specific AI insight has been generated for MSLE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.52$13.39
$7.70
Fundamentals
Market Cap$160M
P/E Ratio—
EPS$-1.70
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding20.8M
MSLE News
14 articles- Satellos to Present at the Bloom Burton & Co. Healthcare Investor ConferenceYahoo Finance·Apr 9, 2026
- Here Are Monday’s Top Wall Street Analyst Research Calls: Avis Budget, Carvana, Dow, Kratos Defense, Netflix, Northern Trust, PayPay,Twilio, Tyson Foods and More247 Wall St·Apr 6, 2026
- Satellos Bioscience: Q4 Earnings SnapshotYahoo Finance·Mar 27, 2026
- Satellos Reports 2025 Financial Results and Highlights Recent Company ProgressYahoo Finance·Mar 27, 2026
- Satellos Up Near 10% In US Premarket As Presents Interim SAT-3247 Clinical and Biomarker Data in DMD at Florida ConferenceYahoo Finance·Mar 10, 2026
- Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific ConferenceYahoo Finance·Mar 10, 2026
- Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific ConferenceYahoo Finance·Feb 24, 2026
- Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular DystrophyYahoo Finance·Feb 18, 2026
- Satellos to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 17, 2026
- Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular DystrophyYahoo Finance·Feb 12, 2026
- Satellos price target raised to $40 from $5 at OppenheimerYahoo Finance·Feb 11, 2026
- Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 10, 2026
- Satellos Closes US$57.2 Million Public Offering in Canada and the United StatesYahoo Finance·Feb 9, 2026
- Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional SharesYahoo Finance·Feb 9, 2026
All 14 articles loaded
Price Data
Open$7.84
Previous Close$8.00
Day High$7.88
Day Low$7.27
52 Week High$13.39
52 Week Low$4.52
52-Week Range
$4.52$13.39
$7.70
Fundamentals
Market Cap$160M
P/E Ratio—
EPS$-1.70
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume22K
Avg Volume (10D)—
Shares Outstanding20.8M
About Satellos Bioscience Inc
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company is headquartered in Toronto, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—